Presence of Systemic Inflammatory Response Syndrome Predicts a Poor Clinical Outcome in Dogs with a Primary Hepatitis by Kilpatrick, Scott et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Presence of Systemic Inflammatory Response Syndrome
Predicts a Poor Clinical Outcome in Dogs with a Primary
Hepatitis
Citation for published version:
Kilpatrick, S, Dreistadt, M, Frowde, P, Powell, R, Milne, E, Smith, S, Morrison, L, Gow, AG, Handel, I &
Mellanby, RJ 2016, 'Presence of Systemic Inflammatory Response Syndrome Predicts a Poor Clinical
Outcome in Dogs with a Primary Hepatitis' PLoS One, vol. 11, no. 1, e0146560. DOI:
10.1371/journal.pone.0146560
Digital Object Identifier (DOI):
10.1371/journal.pone.0146560
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
PLoS One
Publisher Rights Statement:
© 2016 Kilpatrick et al. This is an open access article distributed under the terms of the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
RESEARCH ARTICLE
Presence of Systemic Inflammatory Response
Syndrome Predicts a Poor Clinical Outcome in
Dogs with a Primary Hepatitis
Scott Kilpatrick1, Margaret Dreistadt1, Polly Frowde2, Roger Powell3, Elspeth Milne1,
Sionagh Smith1, Linda Morrison1, AdamG. Gow1, Ian Handel1, Richard J. Mellanby1*
1 Royal (Dick) School of Veterinary Studies and The Roslin Institute, The University of Edinburgh, Hospital
for Small Animals, Easter Bush Veterinary Centre, Roslin, Midlothian, United Kingdom, 2 Davies Veterinary
Specialists Limited, Manor Farm Business Park, HighamGobion, Herts, United Kingdom, 3 PTDS, Unit 2a,
Manor Farm Business Park, HighamGobion, Herts, United Kingdom
*Richard.Mellanby@ed.ac.uk
Abstract
Primary hepatopathies are a common cause of morbidity and mortality in dogs. The underly-
ing aetiology of most cases of canine hepatitis is unknown. Consequently, treatments are
typically palliative and it is difficult to provide accurate prognostic information to owners. In
human hepatology there is accumulating data which indicates that the presence of systemic
inflammatory response syndrome (SIRS) is a common and debilitating event in patients
with liver diseases. For example, the presence of SIRS has been linked to the development
of complications such as hepatic encephalopathy (HE) and is associated with a poor clinical
outcome in humans with liver diseases. In contrast, the relationship between SIRS and clini-
cal outcome in dogs with a primary hepatitis is unknown. Seventy dogs with histologically
confirmed primary hepatitis were enrolled into the study. Additional clinical and clinicopatho-
logical information including respiratory rate, heart rate, temperature, white blood cell count,
sodium, potassium, sex, presence of ascites, HE score, alanine aminotransferase (ALT),
alkaline phosphatase (ALP), bilirubin and red blood cell concentration were available in all
cases. The median survival of dogs with a SIRS score of 0 or 1 (SIRS low) was 231 days
compared to a median survival of 7 days for dogs with a SIRS score of 2, 3 or 4 (SIRS high)
(p<0.001). A Cox proportional hazard model, which included all other co-variables, revealed
that a SIRS high score was an independent predictor of a poor clinical outcome. The effect
of modulating inflammation on treatment outcomes in dogs with a primary hepatitis is
deserving of further study.
Introduction
Primary hepatopathies are a common cause of morbidity and mortality in dogs, with a recent
study reporting that over 10 per cent of dogs had evidence of chronic hepatitis at post mortem
examination [1–3]. Primary hepatitis includes all inflammatory disorders of the hepatic
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parenchyma [4]. In contrast to human medicine, where the type of hepatitis is defined by the
inciting cause, few causes of chronic hepatitis have been identified in the dog, and the majority
of cases are idiopathic [4]. Although primary hepatitis can be readily diagnosed in dogs
through histological examination of a liver biopsy, it remains a challenging and difficult disease
to treat [1, 5]. Furthermore, it is difficult to offer clients an accurate prognosis at the time of
diagnosis [2].
There is growing evidence that systemic inflammatory response syndrome (SIRS) is a com-
mon and serious disorder among human patients with liver diseases [6–8]. It has been sug-
gested that the presence of SIRS can lead to a further deterioration in liver function resulting in
significant morbidity and mortality [9, 10]. The presence of SIRS can compromise the function
of various organ systems resulting in Multiple Organ Dysfunction Syndrome (MODS) [11].
Hospitalised human patients with cirrhosis and SIRS have more severe hepatic encephalopathy
(HE), are more likely to develop hepatorenal syndrome and have non-reversible renal dysfunc-
tion [12]. In acute liver failure, the presence of SIRS, whether or not precipitated by infection,
has been implicated in the progression of HE, reducing the chances of transplantation and con-
ferring a poorer prognosis [13]. Furthermore, higher SIRS scores are related to the develop-
ment of acute liver failure in patients with pre-existing hepatitis [14].
There is a clear need to clarify the relationship between inflammation and outcome in dogs
with a primary hepatitis. A more detailed understanding of the relationship between inflamma-
tion and clinical outcomes may lead to novel therapeutic approaches. The aim of this study was
to determine the prevalence of systemic inflammation in a cohort of dogs with primary hepati-
tis, and to then examine the relationship between systemic inflammation and patient survival.
Materials and Methods
Consecutive cases of dogs diagnosed with primary hepatopathies at the Royal (Dick) School of
Veterinary Studies or Davies Veterinary Specialists, were considered for inclusion in the study.
Cases were only included if the dog had histopathological confirmation of primary parenchy-
mal hepatic disease. Information on the signalment and previous medical treatment was
extracted from the clinical records. The histopathological diagnosis was classified according to
WSAVA (World Small Animal Veterinary Association) criteria by a board certified pathologist
[4]. All blood samples were taken by a veterinary surgeon as part of routine clinical manage-
ment of each patient. The study was approved by The University of Edinburgh Ethics Research
Committee and the owners of the dogs gave permission for their animals’ data to be used in
this study.
The presence of HE was evaluated using previously described criteria [15]. The dog was
considered to have HE if it had clinical signs of lethargy, inappropriate behavior, disorienta-
tion, circling, head pressing or seizures [16]. If the dog displayed none of these signs, it was
considered not to have HE. The presence of ascites was documented if confirmed by ultra-
sound evaluation. Details of heart rate, respiratory rate, temperature, haematology profile and
biochemistry profile were recorded. A SIRS score was calculated for each dog using methodol-
ogy previously described [17]. The SIRS score could range from 0–4 as each dog was given 1
point when they met each of the following criteria: respiratory rate greater than 20 min heart
rate greater than 120 min; total white blood cell (WBC) count less than 6 or greater than 16
x109 L and rectal temperature less than 38.1°C or greater than 39.2°C Therefore, a SIRS score
could range from 0 to 4.
Survival of the cohort was initially examined using Kaplan Meier analysis. As some of the
dogs were alive at the end of follow up, Cox proportional hazard analysis was used to estimate
the association between survival and selected co-variates. Initially, a uni-variable analysis was
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performed which explored the relationship between survival and SIRS score. To determine if
this relationship persisted in the presence of other possible other confounding variables, a mul-
tivariable Cox proportional hazard model was constructed which included SIRS score of 0 or 1
(SIRS low) or SIRS score of 2, 3 or 4 (SIRS high), sodium, potassium, sex, ALT, ALP, bilirubin,
red blood cell count, presence of ascites, age and HE score. A final model was built based on
step wise removal of variables from the initial comprehensive model using AIC as a measure of
parameter penalised model fit. To confirm the model structure, the impact on AIC of both
dropping each of the final variables and adding back in the dropped variables was investigated.
Results are presented as a hazard ratio with 95% CI. Statistical analysis was performed in R sta-
tistical software package (R Development Core Team (2012)).
Results
Eighty cases of histologically confirmed primary hepatopathies were identified. Ten dogs were
excluded from the study due to incomplete clinical records. The 70 dogs included in this study
comprised of 29 different pure breeds and eight cross-breeds. The sex distribution comprised
of 12 entire males, 24 neutered males, 24 neutered females and 10 entire female dogs. The
median age was 75 months (range 6 to 180 months). The diagnosis of hepatitis was histologi-
cally confirmed from samples collected at post-mortem examination in 9 cases, and from a per-
cutaneous spring-loaded biopsy instrument in 12 cases. Forty nine samples were collected by
surgical biopsy techniques. Fifty cases were diagnosed with chronic hepatitis (Fig 1), 10 cases
with acute hepatitis, eight cases with cirrhosis (Fig 2) and two cases with copper associated hep-
atitis (Fig 3). Fifty-seven dogs were dead at follow up and 13 were alive. Seventeen dogs had a
SIRS score of 0, 22 had a score of 1, 25 had a score of 2, five had a score of 3 and one dog had a
score of 4.
Fig 1. Liver from a case of chronic hepatitis with islands of hepatocytes separated by bands of
fibroblasts and collagen, andmoderate numbers of macrophages, lymphocytes and plasma cells.
Haematoxylin and eosin, scale bar = 50 μm.
doi:10.1371/journal.pone.0146560.g001
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The median survival time of the 70 dogs was 38.5 days (95% CI 20–215). To explore the
relationship between a systemic inflammatory response and survival, the median survival of
dogs with a SIRS low and dogs with a SIRS high was estimated. The median survival of SIRS
low dogs was 231 days (95% CI 78-not available/ days) and median survival of SIRS high was 7
Fig 2. Liver from a case of chronic hepatitis and early cirrhosis showing disruption of the lobular
architecture and dissecting fibrosis (green).Masson’s trichrome, scale bar = 100 μm.
doi:10.1371/journal.pone.0146560.g002
Fig 3. Liver from a case of chronic hepatitis with intracytoplasmic copper accumulation in hepatocytes.
Rhodanine red, scale bar = 50 μm.
doi:10.1371/journal.pone.0146560.g003
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days (95% CI 3-25/ days) (p<0.001) (Fig 4). To assess whether this relationship persisted in the
presence of other co-variates, a Cox proportional hazard model was built. The initial model
included SIRS high or low, presence of ascites, HE score, sex, sodium, potassium, ALT, ALP,
bilirubin, age, sex and red blood cell count (S1 File). The final model after variable selection
included SIRS, bilirubin, red blood cell concentrations and age (Table 1). The impact of vari-
ables dropped from the model was confirmed by calculating the impact on model fit (Δ AIC)
when they were individually added back into the model (Table 2).
Discussion
In this large two centre study, we have examined for the first time, the relationship between
SIRS, a simple marker of inflammation, and clinical outcome in dogs with primary hepatitis
The central finding of this study was that the dogs with a primary hepatitis and a SIRS score of
2, 3 or 4 had a significantly worse clinical outcome than dogs with a SIRS score of 0 or 1. This
provides evidence that the presence of systemic inflammation is associated with a poorer clini-
cal outcome in dogs, which is similar to human patients with liver disease. The presence of
SIRS was a major predictor of multiple organ failure and strongly correlated with short term
mortality in patients with alcoholic hepatitis [7]. In addition, SIRS has recently been associated
with acute on chronic liver failure (ACLF) [18].
Fig 4. Kaplan-Meier plot of survival time in days by SIRS high (red solid line) and SIRS low (blue
dotted line). Tick marks show censored events.
doi:10.1371/journal.pone.0146560.g004
Table 1. Hazard Ratios and 95% confidence interval for terms in final Cox proportional hazard model.
Δ AIC is the increase in AIC if the term is dropped from the model. A positive Δ AIC equates to a poorer model
fit.
Hazard Ratio (95% CI) Δ AIC
SIRS 3.575 (1.857–6.884) 13.3
Bilirubin 1.003 (1.001–1.005) 5.98
Red blood cell 0.768 (0.596–0.990) 2.14
Age 0.909 (0.827–1.000) 1.94
doi:10.1371/journal.pone.0146560.t001
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Inflammation may be associated with a poor outcome in dogs and humans with liver disease
for several reasons. Intestinal bacterial overgrowth and altered gut permeability in patients
with liver disease is hypothesised to lead to increased translocation of bacteria and endotoxin
into the portal circulation [9]. Factors leading to SIRS development in liver disease include the
impaired phagocytic function of the reticuloendothelial system which allows endotoxin to
reach the systemic circulation in high concentrations [13]. Lipopolysaccharide (LPS) concen-
trations in the peripheral and portal circulation have been shown to be increased in people
with liver cirrhosis. Importantly, LPS concentrations have been shown to predict mortality in
patients with alcoholic hepatitis[7]. Endotoxin can activate monocytes and release pro-inflam-
matory cytokines which have been implicated in the development of hepatic complications
such as HE, ascites and variceal bleeding [19]. The disturbances in systemic and hepatic hae-
modynamics in alcohol-related liver failure (ACLF) have also been associated with dysregu-
lated inflammation, multi-organ failure and marked activation of the sympathetic nervous
system [7]. These abnormalities predict high mortality rates in these patients [8].
In our study, the proportion of dogs which had an infection was not accurately defined. In a
recent study of human patients with alcoholic hepatitis and SIRS, over 60% of patients had no
evidence of infection, based on clinical or microbiological criteria [8]. Understanding the
pathophysiology of sterile inflammation in patients with liver disease, with the ambition of
developing targeted therapies, is one of the major challenges in contemporary hepatology.
Predicting the course and prognosis of disease is an important part of veterinary and
human clinical practice and the development of new prognostic markers with documented sig-
nificance is an important focus of human and veterinary research. Various factors have been
demonstrated as negative prognostic indictors in dogs with primary hepatitis [20]. These
include jaundice, abdominal fluid wave, microhepatica, ascites, enlarged portal lymph nodes,
hypoalbuminemia and left shift of neutrophils in the peripheral blood [1]. Consistent with our
study, total serum bilirubin was a negative prognostic indicator in idiopathic canine chronic
hepatitis [2]. High bilirubin concentrations have also been documented to be associated with a
negative outcome in human patients [21, 22]. Furthermore, our prognostic link with low red
blood cell count is consistent with the prediction of poor post-surgical survival associated with
reduced red blood cell counts in human patients with primary liver cancer [23] and end stage
liver disease [24].
Another finding of this study was that abnormal serum sodium concentrations were not
commonly observed in dogs with primary hepatitis. This observation contrasts with the find-
ings from studies of humans with liver disease where hyponatremia is frequently observed [25–
27]. For example, in a prospective study of 997 patients with cirrhosis the prevalence of low
serum sodium concentration, defined as a serum sodium135 mmol/l,130 mmol/l,125
mmol/l or120 mmol/l, was 49.4%, 21.6%, 5.7%, and 1.2%, respectively [28]. Borroni et al.
Table 2. Δ AIC for terms not included in final model when added back in final model. A positive Δ AIC
equates to a poorer model fit.
Δ AIC
Sodium 0.03
Potassium 1.77
Sex 2.75
Ascites 1.94
HE score 4.77
ALP 1.98
ALT 0.68
doi:10.1371/journal.pone.0146560.t002
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reported hyponatraemia in 29.8% of patients admitted for management of cirrhosis, as defined
by a serum sodium concentration of130 mmol/l [29]. Furthermore, the prevalence of hypo-
natremia was 26% in a population of paediatric patients with end stage liver disease awaiting
liver transplantation (as defined by a serum sodium concentration of130 mmol/l) [30]. It
remains unclear why humans frequently develop hyponatraemia with liver disease while dogs
do not. We hypothesise that the differences may reflect the different causes of liver disease in
dogs compared to humans.
Several studies in human patients with liver disease have examined the role of circulating
biomarkers as adjunctive markers of systemic inflammation, such as LPS, procalcitonin and C
reactive protein [31–33]. Cytokines, including interleukin-6 (IL-6), interleukin-8 (IL-8) and
tumour necrosis factor (TNF), are key mediators of the inflammatory response [11]. Several
studies have measured circulating cytokine concentrations in patients with liver disease. One
marker that has been investigated in some detail is IL-6 [34–36]. Increased serum concentra-
tions of IL-6 have been found in people with different inflammatory diseases and has been cor-
related with the severity of disease, prognosis and outcome [37]. Higher circulation levels of
IL-6 were significantly associated with a higher risk of developing hepatocellular carcinoma
[38]. IL-6 has also been shown to be a useful prognostic marker for canine critical care patients
[39].
Our study demonstrates the need to understand more about the development of systemic
inflammation in dogs with liver disease and to establish whether reducing systemic inflamma-
tion improves outcomes.
Conclusion
In conclusion, a high SIRS score was associated with poorer long term survival in our study of
dogs with primary hepatitis Our study demonstrates the need to understand more about the
causes and consequences of inflammation in dogs with liver disorders. Our study demonstrates
the need to understand more about the development of systemic inflammation in dogs with
liver disease and to establish whether reducing systemic inflammation improves patient out-
comes. The impact of ameliorating inflammation in patients with hepatitis is ill defined.
Although prednisolone is widely used as a first line treatment for hepatitis in both dogs and
humans, its therapeutic benefits remain ill-defined in both species [40–43].
Supporting Information
S1 File. Clinical and biochemical data from the 70 dogs with histologically confirmed hepa-
titis reported in this study.
(XLSX)
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